107 related articles for article (PubMed ID: 16100843)
1. Antiangiogenic therapy in cancer: a new era has begun.
Grothey A
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):5-6. PubMed ID: 16100843
[No Abstract] [Full Text] [Related]
2. Antiangiogenic agents in cancer therapy.
Lenz HJ
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy for cancer: current and emerging concepts.
Jain RK
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):7-16. PubMed ID: 15934498
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of antiangiogenic therapies.
Hudis CA
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):26-31. PubMed ID: 15934500
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
6. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
7. [Are antiangiogenic antibodies universal for solid tumor?].
Ray-Coquard I; Bachelot T; Saba C; Confavreux C; Brantus JF; Rustam F; Ghesquière H; Sebban C; Biron P; Guastalla JP; Blay JY
Bull Cancer; 2007 Jul; 94 Spec No():S191-6. PubMed ID: 17846004
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in breast cancer: the best is yet to come?
Puhalla S; Brufsky A
Oncology (Williston Park); 2009 Apr; 23(4):332, 335. PubMed ID: 19476262
[No Abstract] [Full Text] [Related]
9. In reference to hereditary hemorrhagic telangiectasia/avastin.
Bachmann-Harildstad G
Laryngoscope; 2010 Oct; 120(10):2134. PubMed ID: 20824638
[No Abstract] [Full Text] [Related]
10. Intravitreous bevacizumab and blood pressure: does 'safe' mean 'safe enough'?
Ziemssen F; Folprecht G; Ziemssen T
Acta Ophthalmol Scand; 2007 Aug; 85(5):573-4; author reply 574-5. PubMed ID: 17474969
[No Abstract] [Full Text] [Related]
11. Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase.
Svensson KJ; Welch JE; Kucharzewska P; Bengtson P; Bjurberg M; Påhlman S; Ten Dam GB; Persson L; Belting M
Cancer Res; 2008 Nov; 68(22):9291-301. PubMed ID: 19010902
[TBL] [Abstract][Full Text] [Related]
12. Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?
Bopp S
Br J Ophthalmol; 2007 Oct; 91(10):1259-60. PubMed ID: 17895411
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.
Kernt M; Neubauer AS; Kampik A
Acta Ophthalmol Scand; 2007 Feb; 85(1):119-20. PubMed ID: 17244226
[No Abstract] [Full Text] [Related]
14. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
Mir O; Mouthon L; Alexandre J; Mallion JM; Deray G; Guillevin L; Goldwasser F
J Natl Cancer Inst; 2007 Jan; 99(1):85-6. PubMed ID: 17202119
[No Abstract] [Full Text] [Related]
15. Optimizing outcomes with bevacizumab by better targeting patients and tumors.
DeMichele A; Fox KR
Oncology (Williston Park); 2009 Apr; 23(4):339-40. PubMed ID: 19476263
[No Abstract] [Full Text] [Related]
16. Antiangiogenic therapy for cancer: an update.
Shojaei F; Ferrara N
Cancer J; 2007; 13(6):345-8. PubMed ID: 18032969
[TBL] [Abstract][Full Text] [Related]
17. Cancer. Encouraging results for second-generation antiangiogenesis drugs.
Marx J
Science; 2005 May; 308(5726):1248-9. PubMed ID: 15919970
[No Abstract] [Full Text] [Related]
18. New oncology strategy: molecular targeting of cancer cells.
Capriotti T
Medsurg Nurs; 2004 Jun; 13(3):191-5. PubMed ID: 15219169
[No Abstract] [Full Text] [Related]
19. Intravitreal bevacizumab for retinal capillary haemangioma: longterm results.
Ach T; Thiemeyer D; Hoeh AE; Schaal KB; Dithmar S
Acta Ophthalmol; 2010 Jun; 88(4):e137-8. PubMed ID: 19681788
[No Abstract] [Full Text] [Related]
20. Reflux after intravitreal injection of bevacizumab.
Boon CJ; Crama N; Klevering BJ; van Kuijk FJ; Hoyng CB
Ophthalmology; 2008 Jul; 115(7):1270; author reply 1271. PubMed ID: 18598829
[No Abstract] [Full Text] [Related]
[Next] [New Search]
